Search for a trial | Research with human participants

121 results

A phase I followed by a randomized phase II trial of two cycles carboplatin-olaparib followed by olaparib monotherapy versus capecitabine in BRCA-1 or -2 mutated Her2 negative advanced breast cancer as first line treatment (REVIVAL study)

Approved WMORecruitment stopped

Part 1: Determine the Recommended Phase II Dose